Jacob S Tanguay
Overview
Explore the profile of Jacob S Tanguay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
78
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
James N, Ingleby F, Clarke N, Amos C, Attard G, Brawley C, et al.
JNCI Cancer Spectr
. 2022 Jul;
6(4).
PMID: 35877084
Background: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome,...
2.
James N, Clarke N, Cook A, Ali A, Hoyle A, Attard G, et al.
Int J Cancer
. 2022 Apr;
151(3):422-434.
PMID: 35411939
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic...
3.
Rush H, Murphy L, Morgans A, Clarke N, Cook A, Attard G, et al.
J Clin Oncol
. 2021 Nov;
40(8):825-836.
PMID: 34757812
Purpose: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate...
4.
Thomas B, Smith C, Evans J, Button M, Kumar S, Palaniappan N, et al.
Med Oncol
. 2013 Sep;
30(4):719.
PMID: 24026658
Docetaxel has been shown to improve survival in patients with metastatic castrate-resistant prostate cancer (mCRPC). There is no clear consensus regarding the optimum duration of chemotherapy. If patients at greater...
5.
Ansari J, Hussain S, Zarkar A, Tanguay J, Bliss J, Glaholm J
Oncol Rep
. 2008 Sep;
20(4):891-6.
PMID: 18813832
Three-weekly docetaxel chemotherapy with prednisolone is now considered standard of care for patients with metastatic hormone refractory prostate cancer (MHRPC). This study reports the efficacy and toxicity of first-line docetaxel...